Aurobindo Pharma

Price chart

Previous close

₹1,804.00

Open

₹1,810.60

Day high

₹1,850.40

Day low

₹1,800.70

Listed on NSE since 19 July 2000.

Futures and options

Futures, 23 Nov expiry

₹1,839.00

Discount to the share price

−7.00 (−0.38%)

Futures open interest

25,825 contracts (−139 today)

Lot size (NOV 26)

550 shares

Source: NSE, 09-Nov-2026 12:04:38, delayed. Option chain · All futures · Lot sizes

Pivot levels

R3

1,840.33

R2

1,822.67

R1

1,811.33

CPR top

1,796.83

Pivot

1,793.67

CPR bottom

1,790.50

S1

1,782.33

S2

1,764.67

S3

1,753.33

From Friday 6 November’s high, low and close (Yahoo Finance). Arithmetic on past prices, not a forecast.

Market value

₹1,03,568 Cr

P/E (trailing)

26.07

EPS (trailing)

₹69.05

Price to book

2.63

Dividend yield

0.78%

Return on equity

10.7%

Debt to equity

0.22

Profit margin

10.8%

Beta

0.02

Volume today

10.97 L

Average volume

8.95 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Aurobindo Pharma’s results filed with NSE, consolidated (the whole group). Net profit is the share of Aurobindo Pharma’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Aurobindo Pharma’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Hyderabad

Employees

29,209

Company website · Profile: Yahoo Finance

No headlines name Aurobindo Pharma in the last day or two.

• Interim Dividend - Rs 7 Per Share

  Dividend · ex-date 11 November 2026

• Buy Back

  Buyback · ex-date 17 April 2026

• Interim Dividend - Rs 4 Per Share

  Dividend · ex-date 8 August 2025

• Annual General Meeting

  Action · ex-date 26 August 2024

• Buy Back

  Buyback · ex-date 30 July 2024

• Interim Dividend - Rs 1.50 Per Share

  Dividend · ex-date 20 February 2024

• Interim Dividend - Rs 3 Per Share

  Dividend · ex-date 20 November 2023

• Annual General Meeting

  Action · ex-date 22 August 2023

Source: NSE. Latest first, 8 of 20.